Home | Publications | Diseases | Alzheimer's place holder
place holder place holder

Alzheimer's

Stakeholder Insight Alzheimer's Disease

PharmaVitae Profile

Publication Date   October 2007
Publisher   Datamonitor
Product Type   Report
Pages   118
ISBN Number   not applicable
Product Code   DAT609
Ask a question about this product?

Price £2,995.00

approximately: $5,596 | €3,799

Summary


This analysis examines the historical and forecast performance for Novo Nordisk in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Content


  • Chapter 1 Executive Summary
    • Key Findings
    • Historical And Forecast Ethical Sales Performance
    • Therapeutic Strategy
    • Launch And Expiry Outlook
    • Externalization, Geographic And Molecule Type Strategies
    • Externalization Strategy
    • Geographic Strategy
    • Molecule Type Strategy
    • Swot Analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Chapter 2 Corporate History
    • Key Findings
    • Background
    • Key Corporate Developments
    • M&A History
    • Nordisk Gentofte And Novo Industri
    • Novo Nordisk And Novozymes
    • M&A Strategy
    • Current Corporate Structure
    • Ethical Pharmaceuticals
    • Current Management Team
  • Chapter 3 Historical Performance
    • Key Findings
    • Introduction
    • Revenue And Growth Rate Analysis, 2001-06
    • Revenue And Growth Rate Vs. Peer Set
    • Product Analysis, 2001-06
    • Growth Drivers
    • Novorapid
    • Novomix
    • Novoseven
    • Levemir
    • Actraphane
    • Growth Resistors
    • Protaphane
    • Operating Revenue And Cost Analysis, 2001-06
    • Operating Revenue/Cost Analysis
  • Chapter 4 Forecast Performance
    • Key Findings
    • Introduction
    • Revenue And Growth Rate, 2006-12
    • Product Analysis, 2006-12
    • Growth Drivers
    • Novoseven
    • Novomix
    • Levemir
    • Liraglutide
    • Novorapid
    • Growth Resistors
    • Novonorm And Protaphane
    • Therapy Area Analysis, 2006-12
    • Therapy Area Focus
    • Launches And Expiries Analysis, 2006-12
    • Launch Portfolio
    • Core Portfolio
    • Expiry Portfolio
    • Launch/Core/Expiry Configuration
    • Externalization Analysis, 2006-12
    • Geographic Analysis, 2006-12
    • Molecule Type Analysis, 2006-12
  • Chapter 5 Key Products And Competitors
    • Key Findings
  • Overview
    • Endocrine, Metabolic & Genetic Disorders
    • Novorapid (Insulin Aspart)
  • Overview
    • Sales Forecast
    • Newsflow
    • Competitive Landscape
    • Novomix (Insulin Aspart/Insulin Aspart Protamine)
  • Overview
    • Sales Forecast
    • Newsflow
    • Competitive Landscape
    • Levemir (Insulin Detemir)
  • Overview
    • Sales Forecast
    • Newsflow
    • Competitive Landscape
    • Liraglutide (Glp-1 Analog)
  • Overview
    • Sales Forecast
    • Newsflow
    • Competitive Landscape
    • Key Competitors
    • Anti-Diabetics: A Growing Marke
    • Norditropin (Somatropin)
  • Overview
    • Sales Forecast
    • Newsflow
    • Competitive Landscape
    • Hematology
    • Novoseven (Eptacog Alpha)
  • Overview
    • Sales Forecast
    • Newsflow
    • Competitive Landscape
    • R&D Pipeline
  • Chapter 6 Appendix
    • Ims Vs. Company-Reported Data Reconciliation
    • References
    • Datamonitor Reports
    • Abbreviations
    • Exchange Rates
  • List Of Tables
    • Table 1: Novo Nordisk Corporate Executive Committee
    • Table 2: Peer Set Overview
    • Table 3: Operating Revenue/Cost Analysis ($M), 2001-06
    • Table 4: Operating Cost Ratio Analysis (% Of Total Revenues), 2001-06
    • Table 5: Product Portfolio Overview, Sales ($M), 2006-12
    • Table 6: Therapy Area Overview, Sales ($M), 2006-12
    • Table 7: Launch Portfolio Overview, Sales ($M), 2006-12
    • Table 8: Core Portfolio Overview, Sales ($M), 2006-12
    • Table 9: Expiry Portfolio Overview, Sales ($M), 2006-12
    • Table 10: Externally Developed Portfolio ($M), 2006-12
    • Table 11: Molecule Type Overview, Sales ($M), 2006-12
    • Table 12: Key Products Overview
    • Table 13: Novorapid: Overview
    • Table 14: Novorapid: Sales Forecast ($M), 2006-12
    • Table 15: Novorapid: Newsflow
    • Table 16: Novomix 30: Overview
    • Table 17: Novomix: Sales Forecast ($M), 2006-12
    • Table 18: Novomix: Newsflow
    • Table 19: Levemir: Overview
    • Table 20: Levemir: Sales Forecast ($M), 2006-12
    • Table 21: Levemir: Newsflow
    • Table 22: Liraglutide: Overview
    • Table 23: Liraglutide: Sales Forecast ($M), 2006-12
    • Table 24: Liraglutide: Newsflow
    • Table 25: Norditropin: Overview
    • Table 26: Norditropin: Sales Forecast ($M), 2006-12
    • Table 27: Norditropin: Newsflow
    • Table 28: Novoseven: Overview
    • Table 29: Novoseven: Sales Forecast ($M), 2006-12
    • Table 30: Novoseven: Newsflow
    • Table 31: Novo Nordisk's R&D Pipeline (Phase I-Registration)
    • Table 32: Novo Nordisk's Indication Broadening Pipeline (Phase I-Registration)
    • Table 33: Exchange Rates, 2006
  • List Of Figures
    • Figure 1: Historical And Forecast Ethical Sales Performance (% Cagr), Novo Nordisk And Mid Pharma Peer Set
    • Figure 2: Therapeutic Focus Vs. Mid Pharma Peer Set (%), 2006
    • Figure 3: Insulin Based Vs. Non-Insulin Based, Dependency 2006-12 (%)
    • Figure 4: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Novo Nordisk
    • Figure 5: Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales), Peer Set
    • Figure 6: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2006
    • Figure 7: Molecule Type, Externalization And Geographic Market Dependency (%) Vs. Peer Set, 2012
    • Figure 8: Swot Analysis Of Novo Nordisk
    • Figure 9: M&A/Divestment History
    • Figure 10: Current Corporate Structure
    • Figure 11: Revenue & Growth Rate (Ethical Sales) ($M), 2001-06
    • Figure 12: Ethical Revenue ($M) And Growth Rate (%) Vs. Peer Set, 2001-06
    • Figure 13: Growth Drivers/Resistor Products Of Historical Revenue Performance ($M), 2001-06
    • Figure 14: Operating Revenue/Cost Analysis ($M), 2001-06
    • Figure 15: Operating Cost Ratio Analysis (% Of Total Revenues), 2001-06
    • Figure 16: Ethical Revenue ($M) And Growth Rate (%), 2006-12
    • Figure 17: Top 5 Products By Sales ($M), 2006
    • Figure 18: Top Five Products By Sales ($M), 2012
    • Figure 19: Growth Drivers And Resistors By Product, 2006-12
    • Figure 20: Key Strategic Products, Sales ($M), 2006-12
    • Figure 21: Ethical Sales By Therapy Area ($M), 2006-12
    • Figure 22: Growth Drivers And Resistors By Therapy Area ($M), 2006-12
    • Figure 23: Ethical Sales By Therapy Area (%), 2006-12
    • Figure 24: Therapy Area Focus Compared With Peer Set (% Total Ethical Sales), 2006
    • Figure 25: Therapy Area Focus Compared With Peer Set (% Total Ethical Sales), 2012
    • Figure 26: Launch Schedule, Sales ($M), 2006-12
    • Figure 27: Core Products Sales Growth ($M), 2006-12
    • Figure 28: Expiry Schedule, Sales ($M), 2006-12
    • Figure 29: Launch, Core And Expiry, Sales ($M), 2006-12
    • Figure 30: Novo Nordisk, Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales)
    • Figure 31: Peer Set, Launch, Core And Expiry, Absolute Sales Growth, 2006-12 (Sales As % Of 2006 Sales)
    • Figure 32: Externalization Dependency, Sales ($M), 2006-12
    • Figure 33: Growth Drivers And Resistors, Externally Vs. Internally Discovered Products, Sales ($M), 2006-12
    • Figure 34: Externalization Dependency Vs. Peer Set, % Total Sales, 2006
    • Figure 35: Externalization Dependency Vs. Peer Set, % Total Sales, 2012
    • Figure 36: Geographical Sales Breakdown ($M), 2006-12
    • Figure 37: Growth Drivers And Resistors By Geography, Sales ($M) 2006-12
    • Figure 38: Us Dependency Vs. Peer Set, % Total Sales, 2006
    • Figure 39: Us Dependency Vs. Peer Set, % Total Sales, 2012
    • Figure 40: Molecule Type Sales Breakdown ($M), 2006-12
    • Figure 41: Molecule Type Sales Breakdown ($M), 2006-12
    • Figure 42: Biologics Dependency Vs. Peer Set, % Total Sales, 2006
    • Figure 43: Biologics Dependency Vs. Peer Set, % Total Sales, 2012
    • Figure 44: Novo Nordisk: Direct Competition In The Type 1/2 Diabetes Market
    • Figure 45: Ims Vs. Company-Reported Ethical Sales Discrepancy ($M), 2006
    • Figure 46: Ims Vs. Company-Reported Ethical Sales Forecast Growth Rates (%), 2006-12